How to Get Molecular Testing for Cholangiocarcinoma in Canada
At C3, we support the use of Next-Generation Sequencing (NGS) for potentially actionable mutations and relevant biliary tract cancer genes as early as possible after diagnosis. It is important to note that not all NGS testing panels are capable of detecting relevant biliary tract cancer mutations such as gene fusions, therefore, we strongly recommend testing via these options below that are fusion partner agnostic NGS testing panels, optimized for cholangiocarcinoma.
​
This is how you can access Comprehensive Genomic Profiling (CGP) for cholangiocarcinoma patients, depending on your patient's geographical location.
Canada (not including Quebec)
​The C3 has partnered with various service providers to offer molecular testing for different parts of Canada.
-
For Ontario, C3 will cover molecular testing, provided by UHN's Laboratory Medicine Program
-
For all other parts of Canada (not including Quebec*), C3 will cover molecular testing provided by OncoHelix
​​
For the testing to be covered by the C3, the patient must be a C3 Member, which includes consenting to the collection of data for the C3 National Registry
​
Please refer your patients to "Join the C3" by going to www.cholangio.ca/join
Any test orders for patients who have not signed up will result in delays or for Ontario patients, it may result in only receiving Standard of Care for FGFR testing.
​
Please click for more detailed instructions:
Quebec
Quebec is ahead of the curve when it comes to provincial funding for CGP NGS and covers molecular testing through McGill University Health Centre (MUHC) - OPTILAB.
Please click for detailed instructions: